Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) Equity Average (2016 - 2021)

Phio Pharmaceuticals' Equity Average history spans 10 years, with the latest figure at $27.0 million for Q3 2021.

  • For Q3 2021, Equity Average rose 62.99% year-over-year to $27.0 million; the TTM value through Sep 2021 reached $27.0 million, up 62.99%, while the annual FY2020 figure was $9.4 million, 2.9% down from the prior year.
  • Equity Average reached $27.0 million in Q3 2021 per PHIO's latest filing, down from $30.1 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $30.1 million in Q2 2021 to a low of $1.2 million in Q1 2018.
  • Average Equity Average over 5 years is $11.0 million, with a median of $8.9 million recorded in 2020.
  • Peak YoY movement for Equity Average: tumbled 87.44% in 2018, then soared 951.67% in 2019.
  • A 5-year view of Equity Average shows it stood at $2.6 million in 2017, then skyrocketed by 191.24% to $7.7 million in 2018, then dropped by 12.88% to $6.7 million in 2019, then skyrocketed by 113.21% to $14.2 million in 2020, then skyrocketed by 89.99% to $27.0 million in 2021.
  • Per Business Quant, the three most recent readings for PHIO's Equity Average are $27.0 million (Q3 2021), $30.1 million (Q2 2021), and $22.2 million (Q1 2021).